Download Files:
Givosiran
$780 – $2,950
Products Details
Product Description
– Givosiran (ALN-AS1) is a small interfering RNA that targets hepatic aminolevulinate synthase 1 (ALAS1) messenger RNA. Givosiran downregulates ALAS1 mRNA and prevents accumulation of neurotoxic δ-aminolevulinic acid and porphobilinogen levels. Givosiran can be used for the research of acute intermittent porphyria[1][2].
Web ID
– HY-132610
Storage Temperature
– -20°C (Powder, protect from light)
Shipping
– Blue Ice
Applications
– Neuroscience-Neuromodulation
Molecular Formula
– C524H694F16N173O316P43S6
References
– [1]Scott LJ. Givosiran: First Approval. Drugs. 2020 Feb;80(3):335-339.|[2]Balwani M, et, al. Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria. N Engl J Med. 2020 Jun 11;382(24):2289-2301.
CAS Number
– 1639325-43-1
Molecular Weight
– 16300.6 (AS: 7563.9 + SS: 8736.7)
Compound Purity
– 97.90
SMILES
– [Givosiran]
Clinical Information
– Launched
Research Area
– Neurological Disease
Solubility
– 10 mM in H2O
Target
– Small Interfering RNA (siRNA)
Pathway
– Epigenetics
Product type
– Oligonucleotides
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
